Exicure, Inc. (XCUR)

US — Healthcare Sector
Peers: IKNA  ENOB  ELYM  HCWB  ZIVO  RNXT  TPST  CBIO  SCPH  MIST  ONCY  MCRB  LIFE  LUMO  MRKR  PTIX  PMVP  IMNN  CYCC  HSTO  DMAC 

Automate Your Wheel Strategy on XCUR

With Tiblio's Option Bot, you can configure your own wheel strategy including XCUR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol XCUR
  • Rev/Share 0.083
  • Book/Share 1.1236
  • PB 9.309
  • Debt/Equity 0.8764
  • CurrentRatio 4.4523
  • ROIC -0.888

 

  • MktCap 66083874.0
  • FreeCF/Share -0.4828
  • PFCF -22.7092
  • PE -6.4984
  • Debt/Assets 0.3942
  • DivYield 0
  • ROE -3.1972

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Exicure, Inc. (XCUR)

  • IPO Date 2018-05-22
  • Website https://www.exicuretx.com
  • Industry Biotechnology
  • CEO Mr. Andy Yoo
  • Employees 7
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.